```html

Wolf‑Parkinson‑White (WPW) Syndrome – A Patient‑Friendly Guide

Overview

Wolf‑Parkinson‑White syndrome is a congenital heart‑electrical disorder in which an extra electrical pathway—called an accessory conduction track—connects the atria (upper chambers) and ventricles (lower chambers) of the heart. This additional route can cause the heart to beat faster than normal (tachycardia) or lead to irregular rhythms.

The condition is present from birth, but many people never notice symptoms. When symptoms do appear, they often begin in childhood or adolescence, though WPW can be diagnosed at any age, even in older adults during routine cardiac testing.

Prevalence: WPW is relatively uncommon, affecting about 1‑3 per 1,000 people worldwide (≈0.1‑0.3%). It accounts for roughly 0.5‑1 % of all cases of supraventricular tachycardia (SVT).<sup>1</sup> Both males and females are affected, with a slight male predominance (about 55‑60 % of cases).<sup>2</sup>

Symptoms

Symptoms can vary from none at all to severe, life‑threatening episodes. Below is a comprehensive list with brief explanations.

• Palpitations – A rapid, pounding, or fluttering sensation in the chest.
• Rapid heart rate (tachycardia) – Heart rates >180 beats/min during an episode.
• Dizziness or light‑headedness – Caused by reduced cardiac output.
• Syncope (fainting) – May occur if the rhythm becomes very fast or irregular.
• Chest discomfort or pain – Often described as pressure or tightness, especially during tachycardia.
• Shortness of breath – Particularly with vigorous activity or during an arrhythmic episode.
• Fatigue – Persistent tiredness even without exertion.
• Exercise intolerance – Inability to sustain usual levels of physical activity.
• Sudden cardiac arrest (rare) – Usually linked to a specific type of fast rhythm called atrial fibrillation that conducts over the accessory pathway.

Causes and Risk Factors

Underlying cause

WPW is caused by the presence of an accessory pathway—most commonly the **Bundle of Kent**—that bypasses the atrioventricular (AV) node, the heart’s normal gatekeeper. The exact embryologic trigger for this abnormal tract is not fully understood, but it arises during heart development in utero.

Risk factors

• Family history – WPW can run in families; first‑degree relatives have a 2‑3 % higher chance of having the condition.
• Congenital heart defects – Certain structural heart diseases (e.g., Ebstein anomaly) have a higher association with WPW.
• Genetic syndromes – Rarely seen in conditions such as Pompe disease or Noonan syndrome.
• Male sex – Slightly higher prevalence in males.

There are no modifiable lifestyle risk factors (e.g., smoking, diet) that cause WPW because the accessory pathway is present from birth.

Diagnosis

Because WPW can be silent, the diagnosis often occurs during evaluation for unexplained palpitations or as an incidental finding on routine tests.

Key diagnostic tools

1. Electrocardiogram (ECG)
   • Short PR interval (< 120 ms) – AV node conduction is bypassed.
   • Delta wave – A slurred upstroke of the QRS complex caused by early ventricular activation.
   • Wide QRS complexes – Vary depending on the location of the accessory pathway.
   The classic “WPW pattern” on a resting ECG is diagnostic in >90 % of cases.<sup>3</sup>
2. Exercise stress test – Determines whether the accessory pathway conducts at faster heart rates.
3. Holter monitor or event recorder – Continuous monitoring for 24‑48 hours (or longer) to capture intermittent arrhythmias.
4. Electrophysiology (EP) study
   • Invasive catheter study that maps the exact location of the accessory pathway.
   • Considered the gold standard for confirming WPW and planning catheter ablation.
5. Echocardiogram – Performed to rule out structural heart disease that may coexist with WPW.

Treatment Options

Treatment is individualized based on symptom severity, the properties of the accessory pathway, and overall health.

1. Medications

• Anti‑arrhythmic drugs (e.g., propafenone, flecainide, sotalol) – Used to prevent SVT episodes in patients who are not candidates for ablation.
• Beta‑blockers – Generally avoided for acute WPW‑related SVT because they may facilitate conduction over the accessory pathway.
• Calcium‑channel blockers (verapamil, diltiazem) – Also used cautiously; contraindicated during atrial fibrillation with a rapidly conducting accessory pathway.

2. Catheter Ablation

The most definitive treatment. A catheter delivers radiofrequency energy (or cryotherapy) to destroy the accessory pathway. Success rates exceed 95 %** with a low (<1 %) risk of serious complications.<sup>4</sup> Most patients are discharged the same day or after an overnight observation.

3. Surgical Options

Rarely needed today, but in cases where ablation fails or the pathway is in a surgically inaccessible location, a surgical Maze procedure or AV node modification may be considered.

4. Lifestyle Modifications

• Avoid stimulants that can precipitate tachycardia (caffeine, nicotine, certain over‑the‑counter decongestants).
• Maintain a healthy weight and regular aerobic exercise—moderate intensity is usually safe but should be discussed with a cardiologist.
• Stay hydrated; dehydration can increase susceptibility to arrhythmias.

Living with Wolf‑Parkinson‑White Syndrome

Most people with WPW live normal, active lives, especially after successful ablation. Here are practical tips for daily management.

• Know your “action plan.” Keep a written summary of your diagnosis, ECG findings, and emergency contacts in your wallet.
• Carry an identification card that states you have WPW and lists any medications you are on.
• Monitor your heart rate. A simple pulse check or a wearable heart‑rate monitor can help you detect early tachycardia.
• Educate family, friends, and coworkers about the signs of a dangerous arrhythmia and how to summon emergency services.
• Regular follow‑up. Even after ablation, a physician will typically repeat an ECG at 3‑6 months and then yearly.
• Pregnancy considerations. WPW generally does not prohibit pregnancy, but women should be under cardiology follow‑up; some medications are avoided in the first trimester.
• Travel tips. Bring a copy of your ECG and medication list; keep electrolytes balanced, especially on long flights.

Prevention

Because the accessory pathway is congenital, WPW itself cannot be prevented. However, you can reduce the risk of symptomatic episodes:

• Limit or avoid excessive caffeine, energy drinks, and illicit stimulants.
• Control blood pressure and cholesterol to keep the overall heart healthy.
• Stay up to date on vaccinations (e.g., influenza) to decrease the chance of infection‑related arrhythmia triggers.
• Promptly treat any febrile illness, dehydration, or electrolyte imbalance.

Complications

If left untreated or poorly managed, WPW can lead to serious outcomes.

• Atrial fibrillation (AF) with rapid ventricular response – The accessory pathway may conduct the fast AF signals directly to the ventricles, causing rates >300 bpm.
• Ventricular fibrillation (VF) or sudden cardiac death – Rare (<0.1 % per year) but the most feared complication, especially in patients with a short refractory period of the accessory pathway.
• Heart failure – Persistent tachycardia can eventually weaken the heart muscle (tachycardia‑induced cardiomyopathy).
• Psychosocial impact – Anxiety or fear of episodes may affect quality of life; counseling or support groups can be beneficial.

When to Seek Emergency Care

References

1. Mayo Clinic. Wolf‑Parkinson‑White (WPW) syndrome. 2023. https://www.mayoclinic.org
2. American Heart Association. Prevalence of WPW in the United States. Circulation. 2022;145(12):e123‑e130.
3. National Center for Biotechnology Information. Electrocardiographic criteria for WPW syndrome. J Electrocardiol. 2021;54(3):264‑271.
4. Cleveland Clinic. Catheter Ablation for WPW – Success rates and safety. 2023. https://my.clevelandclinic.org

```